SCHEMBL5426435

SCHEMBL5426435

COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC[C@@H]1CCCN(C(=O)CN(C)C)C1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.75
FGFR1 P11362 16/20 0.75
FLT1 P17948 16/20 0.75
EGFR P00533 15/20 0.75
FLT4 P35916 14/20 0.75
EPHA2 P29317 2/20 0.61
EPHB4 P54760 2/20 0.61
EPHB2 P29323 2/20 0.58
PDGFRB P09619 2/20 0.56
TEK Q02763 2/20 0.56
BMPR1B O00238 1/20 0.56
PLK4 O00444 1/20 0.56
CIT O14578 1/20 0.56
GAK O14976 1/20 0.56
EPHB6 O15197 1/20 0.56
RIPK2 O43353 1/20 0.56
ROCK2 O75116 1/20 0.56
STK10 O94804 1/20 0.56
MAP4K4 O95819 1/20 0.56
ABL1 P00519 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5428286 1.00 KDR (0.75) KDRFGFR1FLT1EGFRFLT4
SCHEMBL5428279 1.00 KDR (0.75) KDRFGFR1FLT1EGFRFLT4
SCHEMBL5430765 0.93 KDR (0.75) KDRFGFR1FLT1EGFRFLT4
SCHEMBL5428945 0.87 FLT1 (0.77) KDRFGFR1FLT1EGFRFLT4
SCHEMBL1467082 0.86 KDR (1.00) KDRFGFR1FLT1EGFRFLT4
SCHEMBL1469920 0.86 KDR (1.00) KDRFGFR1FLT1EGFRFLT4
SCHEMBL1467578 0.86 KDR (1.00) KDRFGFR1FLT1EGFRFLT4
SCHEMBL5428610 0.85 EGFR (0.77) KDRFGFR1FLT1EGFRFLT4
SCHEMBL5432127 0.85 KDR (0.77) KDRFGFR1FLT1EGFRFLT4
SCHEMBL5428039 0.84 KDR (0.73) KDRFGFR1FLT1EGFRFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases ASTRAZENCA (SE) 2007-02-01 US claimed
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases ASTRAZENCA (SE) 2007-02-01 US disclosed
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases ASTRAZENCA (SE) 2007-02-01 US disclosed
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases ASTRAZENCA (SE) 2007-02-01 US disclosed
EP-1653965-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES Astrazeneca AB (SE) 2006-05-10 EP disclosed
WO-2005013998-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases FLT4, FLT1, VEGFA KDR 4/4885FGFR1 47/4885FLT1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.